Search
for
Sort by
Research 31–60 of 790
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- Ivarmacitinib stimulates hair regrowth in severe alopecia areata
- A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
- Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
- Advances in the mechanism and new therapies of alopecia areata
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
- Treatment of Lichen Planopilaris With Abrocitinib
- Upadacitinib for Alopecia: Current Evidence and Clinical Insights
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- Upadacitinib for the Management of Alopecia Totalis and Subtotalis in Pediatric Patients: A Case Series
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- JAK kinase pathway inhibitor drugs in patients with moderate-to-severe alopecia: a real-world experience